Genentech plans to invest more than $700 million in a new 700,000-ft2 drug manufacturing facility in Holly Springs, NC. The project is expected to add more than 400 manufacturing jobs when the site is operational and more than 1,500 construction jobs during site development.
The new facility will ultimately support Roche and Genentech’s metabolic medicines portfolio, including next-generation obesity therapeutics. This initial investment could expand in the future based on business needs and the U.S. policy environment, according to Genentech. Roche and Genentech’s current U.S. footprint includes 13 manufacturing and 15 R&D sites across the company’s pharmaceutical and diagnostics divisions and 25,000 employees in 24 sites across eight U.S. states.
“Our new facility near Raleigh, North Carolina, an established biopharmaceutical talent hub, will serve as an important new setting within our manufacturing network to help deliver on the promise of our company’s life-changing science and industry-leading pipeline,” said Ashley Magargee, CEO at Genentech.
“I’m proud that Genentech has chosen North Carolina for its first facility on the East Coast,” added Josh Stein, governor of NC. “This major investment in Holly Springs shows that our state continues to be a leading destination for life sciences and advanced manufacturing.”
